Investor Relations
FoRx Therapeutics is a privately held clinical-stage biotechnology company headquartered in Basel, Switzerland.
Company Overview
FoRx Therapeutics is pioneering precision therapeutics targeting the DNA Damage Response in treatment-resistant cancers.
Our lead program, FORX-428, is a best-in-class PARG inhibitor that is currently being evaluated in a clinical Phase 1 trial (NCT07356453).
FoRx is backed by leading life science investors and has assembled a world-class team with deep expertise in oncology drug discovery and development.
Investor Contact
For investor inquiries, please contact our investor relations team. We welcome discussions with institutional and corporate investors as well as strategic partners.
investors@forxtherapeutics.com
Headquarters
Basel, Switzerland
News & Events
Stay informed about our latest developments, presentations, and corporate announcements.